Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEngineers Gate Manager LP
Latest Disclosed Ownership13,818 shares
Latest Disclosed Value $ 6,170,290
Engineers Gate Manager LP reports 196.27% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 13,818 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $6,170,290 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 4,664 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 196.27% during the quarter. The current value of the position is $5,918,802 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,818 9,154 196.27 6,170 191.86 0.0771
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,664 -10,179 -68.58 2,114 -63.63 0.0251
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,843 14,843 5,813 0.0666
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -11,599 -100.00 0 -100.00
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,599 11,599 4,671 0.0813
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -13,386 -100.00 0 -100.00
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,386 881 7.05 6,274 20.03 0.1415
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,505 4,886 64.13 5,227 68.61 0.1376
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,619 -1,096 -12.58 3,100 2.31 0.0885
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,715 5,422 164.65 3,031 161.66 0.1120
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,293 779 30.99 1,159 46.21 0.0438
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,514 -27,783 -91.70 792 -90.95 0.0331
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,297 27,959 1,195.85 8,749 1,192.32 0.5255
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,338 -2,773 -54.26 677 -52.99 0.0421
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,111 -2,153 -29.64 1,440 -24.05 0.0528
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,264 -2,678 -26.94 1,896 -13.15 0.0742
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,942 -33,802 -77.27 2,183 -72.49 0.0982
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,744 16,851 62.66 7,935 46.35 0.4522
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,893 24,300 937.14 5,422 873.43 0.3487
2021-05-17 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,593 14 0.54 557 -8.69 0.0276
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,579 -9,241 -78.18 610 -81.03 0.0265
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,820 9,410 390.46 3,216 359.43 0.1509
2020-08-17 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,410 -18 -0.74 700 21.11 0.0356
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,428 -12,957 -84.22 578 -82.84 0.0416
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,385 11,654 312.36 3,369 433.07 0.1481
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,731 -11,172 -74.96 632 -76.87 0.0321
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,903 14,903 2,732 0.1508
2017-08-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -4,300 -100.00 0 -100.00
2017-05-05 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,300 4,300 470 0.0467
2016-08-11 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -12,638 -100.00 0 -100.00
2016-05-09 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,638 12,638 0.00 1,005 0.0784
2016-02-05 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 0 0 0.0000
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -2,100 -100.00 0 -100.00
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,100 144 7.36 259 12.12 0.0254
2015-05-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,956 1,956 231 0.0307
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.